A 12-month prospective, nationwide registry study (conducted independently of Abbott Diabetes Care) enrolled 1,365 subjects with type 1 and type 2 diabetes and assessed changes in HbA1c, hypoglycemia, health-related quality of life measures, patient-reported outcome measures, diabetes-related hospital admission rates, and work absenteeism rates. The percentage of patients experiencing a diabetes-related hospital admission decreased from 13.7% to 4.7% over 12 months (P<0.001). The number of patients with any work-associated period of absence in the prior 6 months decreased from 251 (18.5%) at baseline to 53 (7.7%) at 12 months (P<0.001). Additionally, an average reduction in HbA1c (0.4%; P<0.001) was observed.

A retrospective, observational analysis of IBM Watson MarketScan™ commercial claims and Medicare Supplemental databases on a US patient population of 2,463 subjects (age 54.2 ±9.6 years; 52.9% male) over 6 months, analyzed pre- and post-CGM use outcomes of the FreeStyle Libre portfolio. The study evaluated the number of acute diabetes events as a primary diagnosis coded with hyper- or hypoglycemia. Secondary outcomes measured all-cause hospitalizations. Hospitalizations were reduced from 0.420 to 0.283 events/patient-year (HR: 0.68 [0.59-0.78]; P<0.001). Acute diabetes events reduced from 0.180 to 0.072 events/patient-year (HR: 0.39 [95% CI: 0.30-0.51]; P<0.001]).

This multicenter, prospective, non-masked, randomized controlled trial of adult patients (≥18 years) with well-controlled type 1 diabetes (HbA1c ≤7.5%) for ≥5 years on ≥3 SMBG tests daily. The study was conducted in 23 European sites across Sweden, Austria, Germany, Spain, and the Netherlands. The primary outcome was change in time in hypoglycemia (<70 mg/dL) between baseline and 6 months in the full analysis set. Subjects using the FreeStyle Libre portfolio (n = 119) experienced a greater reduction in hypoglycemic events/24h from baseline [(< 55 mg/dL); 0.96 (0.65) to endpoint: 0.56 (0.55)]; than patients using SMBG (n = 120) [(< 55 mg/dL); 0.92(0.73); at 6 months: 0.92 (0.74)], which translated to a 41% reduction in hypoglycemic events (<55mg/dL; P<0.0001).

An open-label, randomized controlled study across 26 European sites in France, Germany, and the UK enrolled adult participants (149 intervention, 75 controls) age ≥18 years with type 2 diabetes who used SMBG ≥10 tests per week and who had been on insulin ≥6 months. The primary outcome was difference in HbA1c at 6 months in the full analysis set. Prespecified secondary outcomes included time in hypoglycemia, effect of age, and patient satisfaction. Subjects using the FreeStyle Libre portfolio experienced a greater reduction in hypoglycemic events/24h from baseline [(<55 mg/dL): 0.34 (0.50); at 6 months: 0.14 (0.24)] than subjects using SMBG [(<55 mg/dL): 0.27 (0.44); at 6 months: 0.24 (0.36)], which translated to a 44% reduction in hypoglycemic events (<55 mg/dL; P=0.0017).

A 12-month prospective, observational, real-world study for 1,913 patients with type 1 diabetes was conducted independently of Abbott Diabetes Care in 3 specialist diabetes centers in Belgium. The number of patients with any work-associated period of absence in the prior 6 months decreased from 111 (5.8%) at baseline to 49 (2.9%) at 12 months (P<0.0001). 

A 12-month prospective, nationwide registry study (conducted independently of Abbott Diabetes Care) enrolled 1,365 subjects with type 1 and type 2 diabetes and assessed changes in HbA1c, hypoglycemia, health-related quality of life measures, patient-reported outcome measures, diabetes-related hospital admission rates, and work absenteeism rates. The percentage of patients experiencing diabetes-related hospital admissions decreased from 13.7% to 4.7% over 12 months (P<0.001). The number of patients with any work-associated period of absence in the prior 6 months decreased from 251 (18.5%) at baseline to 53 (7.7%) at 12 months (P<0.001). Additionally, an average reduction in HbA1c (0.4%; P<0.001) was observed.